RJ Keizer, Y Funahashi, T Semba, J Wanders, JH Beijnen, JHM Schellens, ADR Huitema Evaluation of clinical dosing of E7820 from preclinical and clinical data using a biomarker
|
Fredrik Jonsson (1), Laurent Claret (1), Robert Knight (2), Marta Olesnyskyj (2), Christian Jacques (2), Vincent S. Rajkumar (3), Rene Bruno (1) A Longitudinal Tumor Growth Inhibition Model Based on Serum M-Protein Levels in Patients With Multiple Myeloma Treated by Dexamethasone
|
Alexandre Sostelly (1), Léa Payen (2), Benjamin Ribba (3), Attilio Di Pietro (4), Pierre Falson (4), Pascal Girard (1,5), Michel Tod (1,6) Modelling the interaction between Irinotecan and efflux transporters inhibitors: A KPD tumour growth inhibition model including interaction components.
|
N. Jebabli, I. Salouage, S.Trabelsi, E. Gaïes, H. El jebari, Ch. Belkahia, M. Lakhal, A. Klouz Pharmacokinetic Modelling Of Methotrexate From Routine Clinical Data In Patients With Acute Lymphoblastic Leukemia
|
P. Kellie Turner(1,3), Johanne Bray(1), David Jamieson(1), Aurélie Petain(2), Antonin Schmitt(2), Michael Cole(1), Etienne Chatelut(2), Alan V. Boddy(1) Cyclophosphamide, Methotrexate, and 5-Fluorouracil Population Pharmacokinetic Models with Pharmacogenetic Covariates
|
F. Verga (1) (2), B. You (3), A. Benabdallah (2), F. Hubert (2), C Faivre (1), D. Barbolosi (1) Modeling of the metastatic variability in cancer disease.
|
A.Y. Zhang (1), J.M. Skolnik (1, 2), J.S. Barrett (1) Evaluating the Extent of Chemotherapeutic Contamination from Central Venous Catheters in Children with Cancer and Providing Guidance for Accurate Reporting of PK Parameters
|
Ribba B,, Watkin E., Tod M., Girard P., Grenier E., You B., Wei M., Giraudo E., Freyer G. Combined analysis of tumor size data and histological biomarkers drives the development of a semi-mechanistic model of the effect of the antiangiogenic drug Sunitinib in mice
|
Elena Soto1,7, Ron J Keizer2,7, Iñaki F. Trocóniz1, Alwin DR Huitema2,4, Jos H Beijnen2,3,4, Jan HM Schellens3,4, Jantien Wanders 5, Josep María Cendrós6, Rosendo Obach6, Concepción Peraire6, Lena E Friberg7, Mats O Karlsson7 Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies using diflomotecan and indisulam
|
Garrido M.J.1, Viudez A.2, Rodríguez J.2, Zárate R.2, Navarro I.3, Romero E.1, García-Foncillas J.2, Trocóniz I.F.1 Population pharmacokinetic modelling of unbound and total plasma concentrations of oxaliplatin administered by hepatic arterial infusion to patients with liver-metastases.
|
V. Nock (1, 2), A. Lindauer (3), U. Jaehde (3), C. Kloft (1) Leukopenia following high-dose chemotherapy with autologous stem cell retransfusion in patients with testicular cell cancer
|
H.T. Thai(1), C. Veyrat-Follet(2), N. Vivier (2), C. Dubruc(2), E. Comets(1), F. Mentré(1) , G. Sanderink(2) A mechanism-based model for the population pharmacokinetics of aflibercept in healthy subjects
|
H. Struemper (1), J. Bauman (2), Z. Jonak (2), S. Murray (2), S. Williams (2), M.J. Robertson (3), J.F. Toso (2) Analysis of Biomarker Responses in Phase I Study of rhIL-18 in Combination with Rituximab in Non-Hodgkin’s Lymphoma to Support Phase 2 Dose Selection
|
Jackson K (1), Chedid M (2), Evans R (2) Troconiz IF(3) A Novel PKPD Model to Describe the Interaction of Drug Response of Combination Therapy: An Application in Preclinical Oncology.
|
Anne Drescher (1,2), Andreas Lindauer (1), Anne Christin Pieck (1), Günther Weber (3), Ralf A. Hilger (4), Dirk Strumberg (5), Max E. Scheulen (4), Ulrich Jaehde (1) Pharmacokinetic/Pharmacodynamic Modeling of Platinum-DNA-Adduct Formation in Leukocytes after Oxaliplatin Infusion
|
C.B. Landersdorfer (1), D. London (1), R. Meng (1), C. Lin (1), S. Lin (1), C.-U. Lim (1), L. Queimado (2), S.A. Mousa (3), G.L. Drusano (4), A. Louie (4), F.B. Davis (1), H.-Y. Lin (1), P.J. Davis (1). Pharmacodynamic (PD) Modelling of Anti-Proliferative Effects of Tetraiodothyroacetic Acid (Tetrac) on Human Cancer Cells
|
C. Woloch (1), J. Ciccolini (1), A. Di Paolo(2), A. Iliadis (1) Population Pharmacokinetics of 5FU and its Major Metabolite 5-FDHU in Colorectal Cancer Patients
|
Jeroen Elassaiss-Schaap Allometric scaling in oncology disease progression from xenograft tumor growth to human non-small-cell lung cancer
|
Trame MN(1), Bartelink IH(2), Boos J(3), Boelens JJ(2), Hempel G(1,3) External Evaluation of a Population Pharmacokinetic Model for Dosing Busulfan in Children – Body Surface Area better than Body Weight
|
Rühs H(1), Panetta JC(2), Pui CH(2), Relling MV(2), Jaehde U(1) Homocysteine as biomarker in a semi-mechanistic PK/PD model of methotrexate
|
Martin Fransson(1), Henrik Gréen(2), Jan-Eric Litton(1), Lena E. Friberg(3) Pharmacokinetics of paclitaxel and its metabolites using a mechanism-based model
|
N. Azzopardi, T. Lecomte, D. Ternant, Piller F, M. Ohresser, H. Watier, E. Gamelin, G. Paintaud Pharmacokinetics and concentration-effect relationship of cetuximab in metastatic colorectal cancer
|
G. Würthwein(1), C. Young (1), C. Lanvers-Kaminsky(2), G. Silling(3), G. Hempel(2,4), J. Boos(2), A. H. Groll(2) Population Pharmacokinetics of Liposomal Amphotericin B, Caspofungin and the Combination of Both in Allogeneic Hematopoietic Stem Cell Recipients
|